Ubs Group Ag Kezar Life Sciences, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 7,417 shares of KZR stock, worth $4,005. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,417

Previous 71,509 89.63%

Holding current value

$4,005

Previous $64,000 93.75%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.6 - $0.92 $38,455 - $58,964	-64,092 Reduced 89.63%	7,417 $4,000
Q1 2024 May 13, 2024	BUY	$0.8 - $1.05 $17,868 - $23,451	22,335 Added 45.42%	71,509 $64,000
Q4 2023 Feb 09, 2024	BUY	$0.72 - $1.15 $10,815 - $17,274	15,021 Added 43.98%	49,174 $46,000
Q3 2023 Nov 09, 2023	SELL	$1.08 - $2.54 $3,411 - $8,023	-3,159 Reduced 8.47%	34,153 $40,000
Q2 2023 Aug 11, 2023	SELL	$2.31 - $3.06 $138,569 - $183,560	-59,987 Reduced 61.65%	37,312 $91,000
Q1 2023 May 12, 2023	SELL	$3.13 - $7.31 $403,269 - $941,820	-128,840 Reduced 56.97%	97,299 $304,000
Q4 2022 Feb 08, 2023	BUY	$6.39 - $8.8 $1.29 Million - $1.77 Million	201,514 Added 818.33%	226,139 $1.59 Million
Q3 2022 Nov 10, 2022	BUY	$7.99 - $10.75 $176,802 - $237,876	22,128 Added 886.18%	24,625 $212,000
Q2 2022 Aug 10, 2022	SELL	$4.58 - $17.13 $734,705 - $2.75 Million	-160,416 Reduced 98.47%	2,497 $21,000
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $796,929 - $1.19 Million	64,791 Added 66.03%	162,913 $2.71 Million
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $585,766 - $1.32 Million	78,732 Added 406.04%	98,122 $1.64 Million
Q3 2021 Nov 15, 2021	SELL	$4.85 - $9.73 $228,978 - $459,372	-47,212 Reduced 70.89%	19,390 $167,000
Q2 2021 Aug 13, 2021	BUY	$4.93 - $6.46 $303,653 - $397,890	61,593 Added 1229.65%	66,602 $361,000
Q1 2021 May 12, 2021	SELL	$5.24 - $6.99 $5,109 - $6,815	-975 Reduced 16.29%	5,009 $30,000
Q4 2020 Feb 11, 2021	BUY	$4.77 - $6.58 $10,928 - $15,074	2,291 Added 62.04%	5,984 $31,000
Q3 2020 Nov 12, 2020	SELL	$4.36 - $5.5 $18,089 - $22,819	-4,149 Reduced 52.91%	3,693 $18,000
Q2 2020 Jul 31, 2020	SELL	$3.6 - $7.75 $36,734 - $79,081	-10,204 Reduced 56.54%	7,842 $41,000
Q1 2020 May 01, 2020	SELL	$2.77 - $5.75 $3,340 - $6,934	-1,206 Reduced 6.26%	18,046 $79,000
Q4 2019 Feb 14, 2020	BUY	$2.5 - $4.26 $4,315 - $7,352	1,726 Added 9.85%	19,252 $77,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $7.58 $42,882 - $108,348	14,294 Added 442.26%	17,526 $58,000
Q2 2019 Aug 14, 2019	BUY	$7.09 - $21.9 $22,914 - $70,780	3,232 New	3,232 $25,000
Q1 2019 May 14, 2019	SELL	$16.83 - $23.75 $32,010 - $45,172	-1,902 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$20.21 - $32.9 $1,050 - $1,710	52 Added 2.81%	1,902 $45,000
Q3 2018 Nov 14, 2018	BUY	$15.5 - $21.41 $28,675 - $39,608	1,850 New	1,850 $40,000

Others Institutions Holding KZR

# of Institutions

Shares Held

39.6M

Call Options Held

3.2K

Put Options Held

700

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $36.9M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account